Boosting immune response to fight cancer
Human CD3epsilon co-potentiation to boost immunotherapy
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project ID | NIH-9868156 on NIH RePORTER |
What this research studies
This research investigates a new method to enhance the immune system's ability to recognize and attack cancer cells by manipulating T cell receptors. The approach uses specialized fragments that target the CD3 complex on T cells, making them more responsive to cancer antigens. By combining these fragments with existing immunotherapies, the goal is to improve treatment outcomes for patients with metastatic cancers. The research has shown promising results in animal models, indicating potential effectiveness in humans.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who have been diagnosed with metastatic cancers.
Not a fit: Patients with early-stage cancers or those who do not have metastatic disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy options for patients with metastatic cancers.
How similar studies have performed: Previous research has shown success with similar immunotherapy approaches, indicating a strong potential for this method.
Where this research is happening
Columbia, United States
- University of Missouri-Columbia — Columbia, United States (Active)
Researchers
- Principal investigator: Gil Pages, Diana — University of Missouri-Columbia
- Study coordinator: Gil Pages, Diana
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.